P003 Metabolomics for improved patient stratification in inflammatory bowel disease: Characterisation of the ulcerative colitis metabolome
ECCO'20 Vienna
2020
P004 PN-943, an oral α4β7 integrin antagonist, inhibits MAdCAM1-mediated proliferation and cytokine release from CD4+ T cells independent of trafficking
ECCO'20 Vienna
2020
P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD
ECCO'20 Vienna
2020
P006 3D Multicellular intestine-on-a-chip model for disease modelling and drug discovery
ECCO'20 Vienna
2020
P007 GC1qR driven oxidative phosphorylation is essential for intestinal goblet cell differentiation
ECCO'20 Vienna
2020
P009 The innate cytokines IL-1α and TNF-α induce the expression of Oncostatin M and its type II receptor in human colonic subepithelial myofibroblasts
ECCO'20 Vienna
2020
P010 Measurement of colonic mucosal content of biologics with the use of magnetic resonance imaging (MRI): A pilot study in patients with ulcerative colitis
ECCO'20 Vienna
2020
P011 Dysbiosis and Goblet cells depletion triggers early intestinal barrier dysfunction that precedes gut inflammation in IL-10 deficient mice (IL-10−/−)
ECCO'20 Vienna
2020
P013 The JAK-3 and TYK-2 / STAT pathways are activated in moderate to severe ulcerative colitis
ECCO'20 Vienna
2020
P015 Tricellulin overexpression protects against elevated macromolecule uptake in DSS colitis mice
ECCO'20 Vienna
2020
P017 C86/CD16 macrophages accumulate in the mucosa of B3 patients and could mediate EMT in Crohn’s disease
ECCO'20 Vienna
2020
P018 Per- and polyfluoroalkyl substances (PFAS) are significantly increased in patients with late-onset of ulcerative colitis
ECCO'20 Vienna
2020
P019 Colonic mucosal kinase activity, cytokine and chemokine profiles in inflammatory bowel disease
ECCO'20 Vienna
2020
P020 MAM, an anti-inflammatory protein derived from Faecalibacterium prausnitzii as a biomarker in Crohn’s disease?
ECCO'20 Vienna
2020